Table 2.
Pyrotinib-related treatment administration.
| Pyrotinib-related schemes | No (%), (n=137) | |
|---|---|---|
| Lines of systematic therapy of pyrotinib | ||
| 1 | 37 (27.01) | |
| 2 | 49 (35.77) | |
| ≥3 | 51 (37.23) | |
| Regimens | ||
| Pyrotinib single agent | 10 (7.30) | |
| Pyrotinib + chemotherapy | ||
| Pyrotinib + Capecitabine | 72 (52.55) | |
| Pyrotinib + Gemcitabine | 2 (1.46) | |
| Pyrotinib + Vinorelbine | 4 (2.92) | |
| Pyrotinib + Paclitaxel | 8 (5.84) | |
| Pyrotinib + Eribulin | 1 (0.73) | |
| Pyrotinib + HER2-targeted therapy | ||
| Pyrotinib + Trastuzumab | 5 (3.65) | |
| Pyrotinib + HER2-targeted therapy + chemotherapy | ||
| Pyrotinib + Trastuzumab + Capecitabine | 8 (5.84) | |
| Pyrotinib + Trastuzumab + Vinorelbine | 1 (0.73) | |
| Pyrotinib + Trastuzumab + Paclitaxel | 7 (5.11) | |
| Pyrotinib + Trastuzumab + Paclitaxel + Carboplatin | 2 (1.46) | |
| Pyrotinib + Trastuzumab + Vinorelbine + Cisplatin | 1 (0.73) | |
| Pyrotinib + Inetetamab + Capecitabine | 1 (0.73) | |
| Pyrotinib + Inetetamab + Paclitaxel | 1 (0.73) | |
| Pyrotinib + endocrine | ||
| Pyrotinib + Tamoxifen | 1 (0.73) | |
| Pyrotinib + Anastrozole | 2 (1.46) | |
| Pyrotinib + Fluvastatin | 2 (1.46) | |
| Pyrotinib + Anastrozole + Goserelin | 2 (1.46) | |
| Pyrotinib + endocrine + HER2-targeted therapy | ||
| Pyrotinib + Goserelin + Trastuzumab + Pertuzumab | 1 (0.73) | |
| Pyrotinib + Leuprorelin + Anastrozole + Trastuzumab | 1 (0.73) | |
| Pyrotinib + endocrine + chemotherapy | ||
| Pyrotinib + Anastrozole + capecitabine | 2 (1.46) | |
| Pyrotinib + Fluvastatin + capecitabine | 1 (0.73) | |
| Pyrotinib + Goserelin +capecitabine | 2 (1.46) | |
| Dosage | ||
| Starting dosage (mg/day) | ||
| 400 | 137 (100) | |
| Dose reduction (mg/day) | ||
| 400-320 | 14 (10.22) | |
| 400-320-240 | 3 (2.19) | |